2024 UK Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

August 2020 | 527 pages | ID: U02779DFF168EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com contains 527 pages and 37 tables.

The report is available by section, and can be customized to specific information needs and budget.

The report presents a comprehensive analysis of the UK hospital cancer diagnostics market, including:

• Major issues pertaining to the UK hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
• Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
• Test volume and sales forecasts for 40 cancer diagnostic procedures performed in UK hospitals.
• Current instrumentation technologies and feature comparison of leading analyzers.
• Sales and market shares of leading suppliers.
• Emerging diagnostic technologies and their potential market applications.
• Product development opportunities.
• Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
• Business opportunities and strategic recommendations for suppliers.

Contains 527 pages and 37 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Breast Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
  27. Oncogenes
      Abl/abl-bcr
      AIB1
      BCL-2
      BRCA1
      CD44
      C-fos
      C-myb
      C-myc
      CYP-17
      Erb-B
      HPC1
      N-myc
      P40
      P51
      P53
      PIK3CA
      PTI-1
      Ras
      Reg
      Sis
      Src and others
  28. Polypeptide Growth Factors
      Basic Fibroblast Growth Factor
      Beta-TGF
      Cachectin (TNT)
      Calmodulin
      ECFR
      Nerve Growth Factor (NGF)
      Epidermal Growth Factor (EGF)
      Ornithine Decarboxylase
      Transferrin
      Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
      Alpha-Interferon
      B Cell Growth Factors
      B Cell Growth Factor (BCGF)
      Gamma-Interferon
      Interleukin-1 (IL-1)
      Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
      N-Acetylglucosamine
      Actin
      Alpha-Actin
      Antineuronal Antibodies
      7B2
      B72.3
      Bax
      BCD-F9
      BLCA-4
      Blood Group Antigens A,B,H
      CA
      CA 72-4/TAG-72
      CA
      CA-242
      CA-549
      CAM
      CAR-3
      Cathepsin-D
      Chromogranin A and B
      Cluster 1 Antigen
      Cluster-5/5A Antigen
      CTA
      CU18
      DR-70
      DU-PAN-2
      Endometrial Bleeding Associated Factor
      Endostatin
      Epithelial Membrane Antigen
      Feulgen Hydrolysis
      Fibronectin
      FSH
      (1->3)-L-fucosyltransferase
      Gastrin-Releasing Peptide (GRP)
      GDCFP-15
      Glucagon
      Glycoamines
      H23
      Her-2
      Human Carcinoma Antigen
      HPA
      HSP27
      Intermediate Filaments
      Cytokeratins/CK18/Cyfra 21-1
      Desmin
      Gliofibrillary Acid Protein
      Neurofilaments
      Vimentin
      KA
      Kinases
      KP16D3
      LAI
      Leukocyte Common Antigen
      Lewis Antigens
      Lysophosphatidic Acid (LPA)
      Ma 695/Ma
      MABDF3
      MAG
      ME1
      Minactivin
      MN/CA9
      MSA
      Mucin Cancer Antigen (MCA)
      Multiple Tumor Suppressor
      Myosin
      NEA-130
      NMP22
      OA-519
      Opioid Peptides
      P-glycoprotein
      Pancreatic Oncofetal Antigen (POA)
      Placental Lactogen
      PR92
      Proliferative Index, Ki-67
      Px
      RB Inactivation/Deletion
      Ret
      SCCL
      Selectin
      Sialic Acid
      Sialyl SSEA-1/SLX
      SN10
      Somatostatin
      TA-90
      TABA
      Tachykinin
      TAG
      TPS
      Troponin
      Tubulin
      VCAM
      VEGF
      Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
  3. Molecular Diagnostics
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
E. Personal Testing

VIII. COUNTRY ANALYSIS

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Dynamics, Trends, Size and Growth
      Volume Forecasts by Test and Market Segment
      Sales Forecasts by Test and Market Segment
      Major Supplier Sales and Market Shares

IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 3  leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
      Abbott
      Affymetrix
      Beckman Coulter/Danaher
      Becton Dickinson
      bioMerieux
      Bio-Rad
      Cepheid
      DiaSorin
      Eiken Chemical
      Elitech Group
      Enzo Biochem
      Fujirebio
      Grifols
      Hologic
      Leica Biosystems
      Ortho-Clinical Diagnostics
      PerkinElmer
      Qiagen
      Roche
      Siemens Healthineers
      Takara Bio
      Thermo Fisher
      Wako and others